Compare uniQure N.V. Ordinary Shares (QURE) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs Wendys Co — how do they compare? uniQure N.V. Ordinary Shares trades at $21.88 (market cap $1.45B), while Wendys Co trades at $6.71 (market cap $1.23B). The key difference: uniQure N.V. Ordinary Shares is the larger of the two by market cap, and Wendys Co pays a 4.35% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Wendys Co for 78 Days on average.
| QURE | WEN | |
|---|---|---|
Market Cap | $1.45B | $1.23B |
Volume | 3,323,243 | 6,130,931 |
Sector | Health | Consumer Cyclical |
52-Week High | $70.59 | $9.33 |
52-Week Low | $9.03 | $6.10 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $707.46M | $4.96B |
Dividend Yield | — | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wendy's (WEN) trades at $6.35, up 0.63% today, but remains near multi-year lows amid a bearish technical signal. The stock shows attractive valuation ratios, including a P/E of 9.76 and P/S of 0.56, with recent earnings beats. However, declining net income margins and a major franchisee bankruptcy highlight operational challenges. Cash flow trends are stabilizing, with 2026 projected net cash flow turning positive to $65 million.
The outlook is cautious; low valuation and dividend yield offer potential value, but persistent sales declines, high debt, and competitive pressures pose significant risks. Analyst consensus is mixed with a 'Reduce' rating, though the $7.58 price target implies upside if turnaround efforts under new CEO Bob Wright gain traction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
